| Trial ID: | L0231 |
| Source ID: | NCT00156962
|
| Associated Drug: |
Epoetin Alfa Dt
|
| Title: |
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Epoetin alfa DT|DRUG: Epoetin alfa RB
|
| Outcome Measures: |
Primary: Subject incidence of adverse events, Entire Study | Secondary: Epoetin alfa antibodies, Entire Study|Changes from baseline laboratory and vital signs, Entire Study
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
850
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-04
|
| Completion Date: |
2007-03
|
| Results First Posted: |
|
| Last Update Posted: |
2008-07-21
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00156962
|
